Global Immunofluorescence Assay Market to Reach USD 3.7 Billion by 2027, Aided by Increasing Chronic Diseases

The global immunofluorescence assay market is dominated by the North American region, owing to increasing research activities, favourable government funding opportunities, presence of major key players in the region, and laboratory automation. Rising prevalence of chronic diseases, cancer incidences and various infectious diseases are attributed to drive the market growth. The rising spending on research and development and healthcare expenditure is also fuelling the market demand. Investment on research and developments results in technological advancement. Government is also taking initiatives to encourage the use of immunofluorescence assay. Various governmental and non-governmental organisations are investing in research, leading to upsurging demand. The improved versions of kits and reagents increases its demand. Factors like growing popularity of drainable ostomy bags, supportive healthcare policies, high number of patients, and a developed healthcare market are expected to fuel the market growth. It is anticipated that emerging markets like India, China, and Brazil will provide lucrative opportunities for players operating in the immunofluorescence assays market in the forecasted period. This can primarily be attributed to the diversified healthcare markets in these countries. Rising prevalence of indirect immunofluorescence is also contributing to the market growth as it gives high sensitivity, easy to change signal color based on changing the second antibody. The COVID-19 pandemic has also positively impacted the growth of immunofluorescence assay due to increase in the demand for immunofluorescence assay products globally as they are used widely for the detection of viral antigens, including coronavirus. However, quality concerns over antibodies, lower signal, high costs of kits, shortage of skilled labour are the major challenges in this market.

The rising competition among the key players is also providing an impetus to the market growth. In March 2021, Thermo Fisher Scientific Inc. (NYSE: TMO) collaborated with Artificial to develop an integrated and comprehensive software automation platform for Thermo Fisher's standardised COVID-19 Testing Platform. The integration will result in increased testing throughout and support global healthcare initiatives. This collaboration enables biopharma and contract services companies to both simplify their lab technicians' interactions with automated systems and more efficiently coordinate the use of their multiple Momentum automated systems, increasing productivity, and minimising user intervention to meet industry needs.

Market Analysis by Product, Types, Application, and Regions:

• On the basis of products, the industry is divided into reagents and kits, instruments, consumables and accessories.
• Based on types, the industry can be divided into indirect immunofluorescence and direct immunofluorescence.
• On the basis of its application, the market can be divided into cancer, infectious diseases, and autoimmune diseases, among others.
• The regional markets for immunofluorescence assay include North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

Key Findings of the Report:

• Rising prevalence of chronic and infectious diseases is driving the growth of immunofluorescence assay market.
• Increasing spending on research and development resulting in technological advancement, boosts the demand for immunofluorescence assay.
• Factors like growing popularity of drainable ostomy bags, supportive healthcare policies, high number of patients, and a developed healthcare market are likely to fuel the demand for immunofluorescence assay.
• Emergence of coronavirus is also propelling the market growth.

Key Offerings of the Report:

• The EMR report gives an overview of the global immunofluorescence assay industry for the periods (2017-2021) and (2022-2027).
• The report also offers the historical (2017-2021) and forecasted (2022-2027) markets for the product, types, application, and regions.
• The report analyses the market dynamics, covering the key demand and price indicators in the market, along with providing an assessment of the SWOT and Porter’s Five Forces models.

The major players in the global immunofluorescence assay industry are Thermo Fisher Scientific Inc., Cell Signaling Technology, Inc., Bio-Rad Laboratories, Inc., Sino Biological Inc., and PerkinElmer Inc., among others. The comprehensive report by EMR looks into the market share, capacity, and latest developments like mergers and acquisitions, plant turnarounds, and capacity expansions of the major players.

About Us

Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The company's expansive and ever-growing database of reports, which are constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.

EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1000 companies to small and medium-sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.

Contact Us:

Expert Market Research
Website: www.expertmarketresearch.com
Email: sales@expertmarketresearch.com
US & Canada Phone no: +1-415-325-5166
UK Phone no: +44-702-402-5790

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.